title: Treatment options for high-risk chronic lymphocytic leukaemia.
abstract: Chronic lymphocytic leukaemia (CLL) is the most common form of leukaemia in the Western world. The natural history of CLL is extremely variable with a survival time from initial diagnosis that ranges from 2 to more than 20 years. Understanding the clinical diversity and allowing the subclassification of CLL into various prognostic groups not only assists in predicting future outcome for patients, but also helps to direct treatment decisions. Chlorambucil and fludarabine were the standard therapy for CLL for decades. Randomized studies have reported superior overall response and progression-free survival (PFS) for fludarabine compared with alkylator-based therapy and for the fludarabine-cyclophospamide (FC) combination over fludarabine alone. More recently the addition of rituximab to the FC regimen (R-FC) has shown significant improvement in overall response, PFS and overall survival compared with FC alone. However, there are patients for whom this regimen still provides less satisfactory results. Within the above studies CLL patients who have some of the poorer prognostic markers, such as unmutated IgVH genes and/or high beta-2 microglobulin (B2M), and those who fail to achieve a minimal residual disease (MRD) negative remission are likely to have a shorter PFS compared with those without these features. Various strategies have been explored to improve the outcome for such patients. These include the addition of agents to a frontline R-FC regimen, use of consolidation and consideration of maintenance. The only group that can be clearly identified pretreatment for whom conventional fludarabine-based therapies produce significantly inferior response rates, PFS and overall survival are the patients who harbour a genetic fault; deletion or mutation or a combination of deletion and mutation of tumour protein p53 (TP53). TP53 inactivation is a less common finding at first treatment but becomes much more common in fludarabine-refractory patients. Alemtuzumab and high-dose corticosteroids have been shown to be effective in this group of CLL patients. Trials combining these two agents have shown improved responses, particularly for those patients with bulky nodal disease for whom alemtuzumab alone may be insufficient. Since the duration of responses remains relatively short, suitable patients should be considered for allogeneic stem cell transplantation according to the European Group for Blood and Marrow Transplantation (EBMT) guidelines. Furthermore, there are a number of other new treatments on the horizon, including humanized antibodies directed against novel targets and small-molecule inhibitors.
authors.affiliation: Department of Haemato-Oncology, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, UK.
authors.forename: Saman
authors.initials: S
authors.lastname: Hewamana
authors.forename: Claire
authors.initials: C
authors.lastname: Dearden
keywords: CLL; high risk; prognosis; treatment
references.citation: Leukemia. 2009 Jan;23(1):212-4
references.pmid: 18818700
references.citation: J Clin Oncol. 2007 Mar 1;25(7):793-8
references.pmid: 17283364
references.citation: J Clin Oncol. 2009 Feb 1;27(4):498-503
references.pmid: 19075274
references.citation: Blood. 2008 Aug 15;112(4):975-80
references.pmid: 18411418
references.citation: Cancer. 2011 Jan 1;117(1):116-24
references.pmid: 20806349
references.citation: Leuk Lymphoma. 2003 Feb;44(2):337-42
references.pmid: 12688354
references.citation: Cancer. 1985 Nov 15;56(10):2369-75
references.pmid: 3899346
references.citation: Lancet. 2010 Oct 2;376(9747):1164-74
references.pmid: 20888994
references.citation: N Engl J Med. 2000 Dec 14;343(24):1750-7
references.pmid: 11114313
references.citation: J Clin Oncol. 2005 May 1;23(13):2971-9
references.pmid: 15738539
references.citation: J Clin Oncol. 2009 Sep 20;27(27):4578-84
references.pmid: 19704063
references.citation: Clin Cancer Res. 2009 Jul 15;15(14):4759-68
references.pmid: 19567591
references.citation: Leukemia. 2008 Nov;22(11):2048-53
references.pmid: 18754025
references.citation: Leuk Lymphoma. 1999 Jun;34(1-2):167-70
references.pmid: 10350345
references.citation: Leukemia. 2008 Jul;22(7):1377-86
references.pmid: 18418404
references.citation: Leukemia. 2007 Jan;21(1):12-7
references.pmid: 17109028
references.citation: Br J Haematol. 2009 Jan;144(1):95-8
references.pmid: 19016732
references.citation: Leuk Lymphoma. 2008 Nov;49(11):2108-15
references.pmid: 19021053
references.citation: Leukemia. 2003 May;17(5):841-8
references.pmid: 12750695
references.citation: J Clin Oncol. 2010 Apr 1;28(10):1749-55
references.pmid: 20194866
references.citation: Blood. 2007 Jun 1;109(11):4679-85
references.pmid: 17299097
references.citation: Leuk Lymphoma. 2007 Dec;48(12):2412-7
references.pmid: 18067017
references.citation: N Engl J Med. 2000 Dec 28;343(26):1910-6
references.pmid: 11136261
references.citation: J Clin Oncol. 2003 Jul 15;21(14):2747-53
references.pmid: 12860954
references.citation: Blood. 2010 Jun 3;115(22):4393-402
references.pmid: 20194898
references.citation: J Clin Oncol. 1991 Jan;9(1):44-9
references.pmid: 1702145
references.citation: J Clin Oncol. 2009 Sep 10;27(26):4378-84
references.pmid: 19652068
references.citation: Clin Cancer Res. 2008 Nov 1;14(21):6907-15
references.pmid: 18980985
references.citation: J Clin Oncol. 2007 Mar 1;25(7):799-804
references.pmid: 17283363
references.citation: Blood. 2008 Jun 1;111(11):5291-7
references.pmid: 18334676
references.citation: Blood. 2002 Aug 15;100(4):1177-84
references.pmid: 12149195
references.citation: Leukemia. 2009 Dec;23(12):2281-9
references.pmid: 19710697
references.citation: Blood. 2011 Aug 25;118(8):2062-8
references.pmid: 21750315
references.citation: Blood. 2008 Jun 15;111(12):5446-56
references.pmid: 18216293
references.citation: Leukemia. 2009 Nov;23(11):2027-33
references.pmid: 19641526
references.citation: Haematologica. 2008 Mar;93(3):475-6
references.pmid: 18310545
references.citation: Blood. 2002 Aug 15;100(4):1410-6
references.pmid: 12149225
references.citation: J Clin Oncol. 2009 Dec 10;27(35):6012-8
references.pmid: 19826119
references.citation: Nouv Rev Fr Hematol (1978). 1988;30(5-6):433-6
references.pmid: 3065739
references.citation: Eur J Cancer. 2010 Aug;46(12):2145-9
references.pmid: 20627536
references.citation: J Clin Oncol. 2010 Apr 1;28(10):1756-65
references.pmid: 20194844
references.citation: Blood. 2008 May 15;111(10):4916-21
references.pmid: 18309034
references.citation: Ann Oncol. 2009 Dec;20(12):2007-12
references.pmid: 19596701
references.citation: Blood. 2006 Feb 1;107(3):885-91
references.pmid: 16219797
references.citation: Cancer. 2010 May 15;116(10):2360-5
references.pmid: 20225334
references.citation: Leukemia. 2009 Oct;23(10):1779-89
references.pmid: 19693094
references.citation: J Clin Oncol. 2005 May 20;23(15):3433-8
references.pmid: 15809449
references.citation: Haematologica. 2010 Jul;95(7):1136-43
references.pmid: 20145270
references.citation: Blood. 2009 Apr 2;113(14):3168-71
references.pmid: 19050308
references.citation: Leukemia. 2002 Jun;16(6):993-1007
references.pmid: 12040431
references.citation: J Clin Oncol. 2006 Jan 20;24(3):437-43
references.pmid: 16344317
references.citation: Blood. 2008 Sep 1;112(5):1923-30
references.pmid: 18577710
references.citation: Lancet. 1996 May 25;347(9013):1432-8
references.pmid: 8676625
references.citation: Haematologica. 2010 Oct;95(10):1705-12
references.pmid: 20511662
references.citation: Blood. 2000 Oct 15;96(8):2723-9
references.pmid: 11023504
references.citation: Blood. 2010 Oct 7;116(14):2438-47
references.pmid: 20595516
references.citation: Clin Cancer Res. 2005 Nov 1;11(21):7757-63
references.pmid: 16278397
references.citation: Blood. 1998 Nov 15;92(10):3804-16
references.pmid: 9808574
references.citation: Leukemia. 2007 Sep;21(9):1885-91
references.pmid: 17568813
references.citation: J Clin Oncol. 2009 Aug 20;27(24):3994-4001
references.pmid: 19597025
references.citation: Cell Death Differ. 2003 Apr;10(4):477-84
references.pmid: 12719725
references.citation: Leukemia. 2009 Nov;23(11):1980-8
references.pmid: 19626051
references.citation: Leuk Lymphoma. 2010 Jan;51(1):85-8
references.pmid: 20055660
references.citation: Blood. 2009 Jul 30;114(5):957-64
references.pmid: 19414856
references.citation: J Clin Oncol. 2006 Dec 1;24(34):5343-9
references.pmid: 17088571
references.citation: Lancet. 2007 Jul 21;370(9583):230-239
references.pmid: 17658394
references.citation: Blood. 2007 Jan 15;109(2):399-404
references.pmid: 17003373
references.citation: Br J Haematol. 2007 May;137(4):355-63
references.pmid: 17456058
references.citation: J Clin Oncol. 2006 May 20;24(15):2337-42
references.pmid: 16618945
references.citation: J Clin Oncol. 1995 Mar;13(3):570-4
references.pmid: 7884417
references.citation: Br J Haematol. 2001 Jul;114(1):70-7
references.pmid: 11472347
references.citation: Blood. 2009 Oct 15;114(16):3382-91
references.pmid: 19605849
references.citation: Blood. 2010 Sep 23;116(12):2078-88
references.pmid: 20522708
references.citation: Haematologica. 2005 Oct;90(10):1435-6
references.pmid: 16219582
references.citation: Blood. 1998 Jun 1;91(11):4342-9
references.pmid: 9596683
references.citation: Leukemia. 2005 Jun;19(6):1029-33
references.pmid: 15830011
references.citation: J Clin Oncol. 2007 Dec 10;25(35):5616-23
references.pmid: 17984186
references.citation: Blood. 2008 Feb 1;111(3):1094-100
references.pmid: 18003886
references.citation: Br J Haematol. 2004 May;125(3):294-317
references.pmid: 15086411
references.citation: Ann Hematol. 2003 Dec;82(12):759-65
references.pmid: 14551737
references.citation: Lancet Oncol. 2006 Jun;7(6):480-8
references.pmid: 16750498
references.citation: Curr Opin Investig Drugs. 2009 Jun;10(6):588-96
references.pmid: 19513948
references.citation: J Clin Oncol. 2008 Nov 1;26(31):5094-100
references.pmid: 18711173
references.citation: Blood. 2008 Oct 15;112(8):3322-9
references.pmid: 18689542
references.citation: Blood. 2004 May 1;103(9):3278-81
references.pmid: 14726385
references.citation: N Engl J Med. 2002 Aug 8;347(6):452-3
references.pmid: 12167696